Cue Biopharma (CUE) director receives 21,800-share restricted stock unit grant

Rhea-AI Filing Summary

Meehan Viola Mong reported acquisition or exercise transactions in this Form 4 filing.

Cue Biopharma, Inc. director Meehan Viola Mong received an equity compensation award of 21,800 shares of Common Stock in the form of restricted stock units. The RSUs were granted at a stated price of $0.00 per share and are held directly. One-third of the shares underlying the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service with the company through each vesting date. Following this award, the reporting person holds 21,800 shares of Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Meehan Viola Mong

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	21,800	$0.00	--

Holdings After Transaction: Common Stock — 21,800 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 21,800 shares Grant price per share: $0.00 Shares following transaction: 21,800 shares +3 more

6 metrics

RSUs granted 21,800 shares Restricted stock unit award of Common Stock to director

Grant price per share $0.00 Stated price per share for the RSU award

Shares following transaction 21,800 shares Total Common Stock holdings after the RSU grant

First vesting date July 9, 2027 One-third of RSUs vest on this date, subject to continued service

Second vesting date July 9, 2028 Second one-third of RSUs vest on this date

Third vesting date July 9, 2029 Final one-third of RSUs vest on this date

Key Terms

restricted stock units ("RSUs"), vest, continued service

3 terms

restricted stock units ("RSUs") financial

"Represents the grant of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vest financial

"One-third of the shares subject to the RSUs vest on each of July 9, 2027..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continued service financial

"subject to the reporting person's continued service with the issuer through each such vest date."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 07:35 PM Accepted by SEC EDGAR 07/10/2026 - 07:35 PM Learn about SEC filing dates

FAQ

What did Cue Biopharma (CUE) director Meehan Viola Mong report in this Form 4?

Director Meehan Viola Mong reported the grant of 21,800 restricted stock units of Cue Biopharma Common Stock. The award is equity compensation and not an open-market purchase or sale.

How many Cue Biopharma (CUE) shares were granted to Meehan Viola Mong and at what price?

Meehan Viola Mong was granted 21,800 shares of Cue Biopharma Common Stock in the form of RSUs at a stated price of $0.00 per share, reflecting a compensation award.

When do Meehan Viola Mong’s Cue Biopharma (CUE) RSUs vest?

The RSUs vest in three equal installments: one-third on July 9, 2027, one-third on July 9, 2028, and one-third on July 9, 2029, subject to continued service with Cue Biopharma.

How many Cue Biopharma (CUE) shares does Meehan Viola Mong hold after this RSU grant?

After the reported RSU grant, Meehan Viola Mong holds 21,800 shares of Cue Biopharma Common Stock, all reported as held with direct ownership.

Is Meehan Viola Mong’s Cue Biopharma (CUE) Form 4 transaction a market buy or sell?

No. The Form 4 reports a grant of restricted stock units, coded as an A transaction for a grant or award acquisition, not an open-market purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meehan Viola Mong

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		A		21,800(1)	A	$0	21,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.

	/s/ Michael Meluzio, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)